Matthew G. Fury, Eric Sherman, Alan L. Ho, Han Xiao, Frank Tsai, Oby Nwankwo, Camelia Sima, Adrian Heguy, Nora Katabi, Sofia Haque and David G. Pfister A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer Cancer 119
Article first published online: 13 FEB 2013 | DOI: 10.1002/cncr.27986
This phase 1 study establishes the safety and tolerability of everolimus added to docetaxel/taxotere and cisplatin as induction chemotherapy for head and neck cancer. Everolimus dose levels that are known to be therapeutic are achieved.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field